In the USA, the drug “Lakembi” was finally approved for the treatment of Alzheimer’s disease
[ad_1]
The US Food and Drug Administration (FDA) confirmed the approval of Eisai-Biogen’s Lakembi for the treatment of Alzheimer’s disease. Previously, the US FDA supported the use of these drugs under an accelerated procedure, and now confirmed the effectiveness of the drug after a large-scale study, Reuters reports. The panel of experts unanimously agreed that the Leqembi study confirmed the benefit of the treatment for early-stage Alzheimer’s patients. All 6 advisers to the commission voted in favor of the Lekembi drug from Eisai ( 4523.T ) and Biogen ( BIIB.O ). Photo: AndrewLozovyi/Depositphotos The next approval of the drug is expected by July 6, which is likely to expand the funding of treatment in the US under the Medicare program. Lakembi could become the first disease-modifying drug ever to reach regulatory approval. According to the Alzheimer’s Association, current treatments only relieve symptoms, but do not change the course of the disease. In January of this year, Lakembi received fast-track approval from the FDA for its ability to remove amyloid plaques from the brain. On June 9, the panel reviewed Eisai’s large study to ensure that the drug benefits patients. A study published in November found that the drug slowed cognitive decline by 27% in patients in the early stages of the disease. At the same time, the use of the drug was associated with serious side effects, such as brain swelling and bleeding or microhemorrhages. It will be recalled that scientists previously found a connection between viral infections and the development of Parkinson’s and Alzheimer’s diseases. Read also: What is it like when your relative has Alzheimer’s (dementia)? Personal stories and scientific explanation
[ad_2]
Original Source Link
